Candel Fast Tracked for CAN-2409 in Pancreatic Cancer

 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.

https://www.globenewswire.com/news-release/2023/12/12/2794671/0/en/Candel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-CAN-2409-in-Pancreatic-Cancer.html